European Journal of Dermatology
MENUThe potential role of serum polyclonal free light chains as markers of immune activation in psoriatic patients Volume 33, issue 1, January-February 2023
Authors
1 Microbiology and Virology unit, Cotugno Hospital, AORN dei Colli, Naples, Italy
2 Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
3 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy
4 Division of Dermatology and Venereology, Department of Medicine Solna, and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden
5 Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
6 Dermatology Unit, University of Campania “Luigi Vanvitelli”, Naples, Italy
* Reprints: Anna Balato
* Those authors equally contributed to this manuscript
- Key words: biological therapies, polyclonal free light chains, psoriasis
- DOI : 10.1684/ejd.2023.4403
- Page(s) : 12-8
- Published in: 2023
Psoriasis (Pso) is a chronic-relapsing inflammatory disease affecting 2-3% of the general population worldwide [1]. Patients suffering from Pso, especially those with a moderate-to-severe form, may present with various comorbidities such as psoriatic arthritis (PsA), inflammatory bowel diseases, metabolic syndrome and a higher cardiovascular risk [2–6]. Therefore, effective long-term control of this pro- inflammatory status is mandatory [4,5]. Over the last decades, the introduction of biotechnological [...]
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License